Bone metastasis: the importance of the neighbourhood

[1]  W. Schiemann,et al.  Mesenchymal stem cells regulate melanoma cancer cells extravasation to bone and liver at their perivascular niche , 2016, International journal of cancer.

[2]  S. Khosla,et al.  Osteoclast TGF‐β Receptor Signaling Induces Wnt1 Secretion and Couples Bone Resorption to Bone Formation , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  A. Zannettino,et al.  Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche , 2015, Nature Communications.

[4]  E. Rutgers,et al.  Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials , 2015, The Lancet.

[5]  I. Fidler,et al.  The challenge of targeting metastasis , 2015, Cancer and Metastasis Reviews.

[6]  I. Holen,et al.  OPG‐Fc inhibits ovariectomy‐induced growth of disseminated breast cancer cells in bone , 2015, International journal of cancer.

[7]  Zhiyu Zhao,et al.  Deep imaging of bone marrow shows non-dividing stem cells are mainly perisinusoidal , 2015, Nature.

[8]  R. Aft,et al.  CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer , 2015, Molecular Cancer Therapeutics.

[9]  R. Greil,et al.  Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial , 2015, The Lancet.

[10]  J. Chirgwin,et al.  The TGF-β Signaling Regulator PMEPA1 Suppresses Prostate Cancer Metastases to Bone. , 2015, Cancer cell.

[11]  A. D'Amico,et al.  Adverse effects of androgen deprivation therapy and strategies to mitigate them. , 2015, European urology.

[12]  Michael Kerger,et al.  Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer , 2015, Nature Communications.

[13]  Cyrus M. Ghajar.  Metastasis prevention by targeting the dormant niche , 2015, Nature Reviews Cancer.

[14]  T. Martin,et al.  Coupling Signals between the Osteoclast and Osteoblast: How are Messages Transmitted between These Temporary Visitors to the Bone Surface? , 2015, Front. Endocrinol..

[15]  M. Nykter,et al.  The Evolutionary History of Lethal Metastatic Prostate Cancer , 2015, Nature.

[16]  Stephen T. C. Wong,et al.  The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. , 2015, Cancer cell.

[17]  M. Kassem,et al.  Skeletal Stem Cells in Space and Time , 2015, Cell.

[18]  I. Holen,et al.  Prostate Cancer Cells Preferentially Home to Osteoblast‐rich Areas in the Early Stages of Bone Metastasis: Evidence From In Vivo Models , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  N. Cacalano,et al.  PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche , 2014, Journal of Translational Medicine.

[20]  I. Holen,et al.  Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone. , 2014, Endocrine-related cancer.

[21]  L. Duong,et al.  Efficacy of a Cathepsin K Inhibitor in a Preclinical Model for Prevention and Treatment of Breast Cancer Bone Metastasis , 2014, Molecular Cancer Therapeutics.

[22]  J. Delaissé,et al.  The reversal phase of the bone-remodeling cycle: cellular prerequisites for coupling resorption and formation , 2014, BoneKEy reports.

[23]  E. Higashihara,et al.  Zoledronic acid improves clinical outcomes in patients with bone metastatic hormone-naïve prostate cancer in a multicenter clinical trial. , 2014, Anticancer research.

[24]  Y. Uekado,et al.  Phase II trial of zoledronic acid combined with androgen-deprivation therapy for treatment-naïve prostate cancer with bone metastasis , 2014, International Journal of Clinical Oncology.

[25]  D. Hose,et al.  Immunomodulatory drugs thalidomide and lenalidomide affect osteoblast differentiation of human bone marrow stromal cells in vitro. , 2014, Experimental hematology.

[26]  Tri Giang Phan,et al.  Real‐time interactive two‐photon photoconversion of recirculating lymphocytes for discontinuous cell tracking in live adult mice , 2014, Journal of biophotonics.

[27]  A. Sundan,et al.  The role of bone morphogenetic proteins in myeloma cell survival. , 2014, Cytokine & growth factor reviews.

[28]  Y. Kunisaki,et al.  Osterix marks distinct waves of primitive and definitive stromal progenitors during bone marrow development. , 2014, Developmental cell.

[29]  N. Carragher,et al.  Developments in preclinical cancer imaging: innovating the discovery of therapeutics , 2014, Nature Reviews Cancer.

[30]  F. Saad,et al.  Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  R. Nolley,et al.  Development of a realistic in vivo bone metastasis model of human renal cell carcinoma , 2014, Clinical & Experimental Metastasis.

[32]  Michael L. Wang,et al.  Osteoblastic niche supports the growth of quiescent multiple myeloma cells. , 2014, Blood.

[33]  I. Benjamin,et al.  Molecular Stress-inducing Compounds Increase Osteoclast Formation in a Heat Shock Factor 1 Protein-dependent Manner* , 2014, The Journal of Biological Chemistry.

[34]  I. Holen,et al.  Zoledronic Acid Has Differential Antitumor Activity in the Pre- and Postmenopausal Bone Microenvironment In Vivo , 2014, Clinical Cancer Research.

[35]  R. Adams,et al.  Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone , 2014, Nature.

[36]  J. Delaissé,et al.  Osteoblast recruitment routes in human cancellous bone remodeling. , 2014, The American journal of pathology.

[37]  P. Garnero,et al.  Periostin and transforming growth factor β‐induced protein (TGFβIp) are both expressed by osteoblasts and osteoclasts , 2014, Cell biology international.

[38]  Sergei A. Vinogradov,et al.  Direct measurement of local oxygen concentration in the bone marrow of live animals , 2014, Nature.

[39]  A. Berger,et al.  Preclinical Activity of the Oral Proteasome Inhibitor MLN9708 in Myeloma Bone Disease , 2014, Clinical Cancer Research.

[40]  R. G. Richards,et al.  Direct Cell-Cell Contact between Mesenchymal Stem Cells and Endothelial Progenitor Cells Induces a Pericyte-Like Phenotype In Vitro , 2014, BioMed research international.

[41]  R. Rabadán,et al.  Leukemogenesis Induced by an Activating β-catenin mutation in Osteoblasts , 2014, Nature.

[42]  T. Martin,et al.  Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit. , 2014, BoneKEy reports.

[43]  F. Giancotti.  Mechanisms Governing Metastatic Dormancy and Reactivation , 2013, Cell.

[44]  M. Freeman,et al.  Doxorubicin-Mediated Bone Loss in Breast Cancer Bone Metastases Is Driven by an Interplay between Oxidative Stress and Induction of TGFβ , 2013, PloS one.

[45]  G. Morgan,et al.  Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment , 2013, Clinical Cancer Research.

[46]  J. Foekens,et al.  Selection of Bone Metastasis Seeds by Mesenchymal Signals in the Primary Tumor Stroma , 2013, Cell.

[47]  S. Duffy,et al.  Patterns of metastatic spread in early breast cancer. , 2013, Breast.

[48]  J. Delaissé,et al.  Understanding coupling between bone resorption and formation: are reversal cells the missing link? , 2013, The American journal of pathology.

[49]  Mina J. Bissell,et al.  The perivascular niche regulates breast tumor dormancy , 2013, Nature Cell Biology.

[50]  F. Schuetz,et al.  Prognostic Value of Disseminated Tumor Cells in the Bone Marrow of Patients with Operable Primary Breast Cancer: A Long-term Follow-up Study , 2013, Annals of Surgical Oncology.

[51]  Li Wang,et al.  BSP Gene Silencing Inhibits Migration, Invasion, and Bone Metastasis of MDA-MB-231BO Human Breast Cancer Cells , 2013, PloS one.

[52]  D. Noh,et al.  Periostin-binding DNA aptamer inhibits breast cancer growth and metastasis. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[53]  Liying Zhang,et al.  A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study. , 2013, European urology.

[54]  K. Pienta,et al.  GAS6 Receptor Status Is Associated with Dormancy and Bone Metastatic Tumor Formation , 2013, PloS one.

[55]  Kenneth J. Pienta,et al.  Recruitment of Mesenchymal Stem Cells Into Prostate Tumors Promotes Metastasis , 2013, Nature Communications.

[56]  Jiake Xu,et al.  HSP90 inhibitors enhance differentiation and MITF (microphthalmia transcription factor) activity in osteoclast progenitors. , 2013, The Biochemical journal.

[57]  A. Neri,et al.  Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules. , 2013, Experimental hematology.

[58]  J. Delaissé,et al.  Increased presence of capillaries next to remodeling sites in adult human cancellous bone , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[59]  N. Raje,et al.  Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy , 2013, Leukemia.

[60]  R. Baron,et al.  Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. , 2013, The Journal of clinical investigation.

[61]  S. Morrison,et al.  Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches , 2013, Nature.

[62]  M. Selig,et al.  Intermittent parathyroid hormone administration converts quiescent lining cells to active osteoblasts , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[63]  E. D. de Vries,et al.  CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy. , 2012, Neoplasia.

[64]  Paul J Hertzog,et al.  Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape , 2012, Nature Medicine.

[65]  G. Morgan,et al.  Effects of bone-targeted agents on cancer progression and mortality. , 2012, Journal of the National Cancer Institute.

[66]  A. Zijlstra,et al.  Stimulation of Host Bone Marrow Stromal Cells by Sympathetic Nerves Promotes Breast Cancer Bone Metastasis in Mice , 2012, PLoS biology.

[67]  Jiake Xu,et al.  Growth Factors , Cytokines , and Cell Cycle Molecules Methotrexate Chemotherapy Promotes Osteoclast Formation in the Long Bone of Rats via Increased Pro-Inflammatory Cytokines and Enhanced NF-B Activation , 2012 .

[68]  J. Reuben,et al.  Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome , 2012, BMC Cancer.

[69]  K. Pienta,et al.  Prevalence of prostate cancer metastases after intravenous inoculation provides clues into the molecular basis of dormancy in the bone marrow microenvironment. , 2012, Neoplasia.

[70]  K. Pienta,et al.  Hypoxia Stabilizes GAS6/Axl Signaling in Metastatic Prostate Cancer , 2012, Molecular Cancer Research.

[71]  P. Neven,et al.  Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial. , 2012, Clinical breast cancer.

[72]  F. Saad,et al.  Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial , 2012, The Lancet.

[73]  J. Massagué,et al.  VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. , 2011, Cancer cell.

[74]  Hong Peng,et al.  Interactions between cancer stem cells and their niche govern metastatic colonization , 2011, Nature.

[75]  Richard O Hynes,et al.  Metastatic cells will take any help they can get. , 2011, Cancer cell.

[76]  F. Saad,et al.  Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[77]  J. Massagué,et al.  Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. , 2011, Cancer cell.

[78]  W. Gregory,et al.  Breast-cancer adjuvant therapy with zoledronic acid. , 2011, The New England journal of medicine.

[79]  G. Roodman,et al.  Bone effects of cancer therapies: pros and cons , 2011, Current opinion in supportive and palliative care.

[80]  M. Seibel,et al.  Vitamin D deficiency promotes prostate cancer growth in bone , 2011, The Prostate.

[81]  T. Guise,et al.  Cancer to bone: a fatal attraction , 2011, Nature Reviews Cancer.

[82]  P. Bianco.  Minireview: The stem cell next door: skeletal and hematopoietic stem cell "niches" in bone. , 2011, Endocrinology.

[83]  P. Bianco.  Bone and the hematopoietic niche: a tale of two stem cells. , 2011, Blood.

[84]  K. Pienta,et al.  Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. , 2011, The Journal of clinical investigation.

[85]  M. Carducci,et al.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.

[86]  L. Matrisian,et al.  TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling. , 2011, Cancer research.

[87]  C. Postenka,et al.  Deletion of the thrombin cleavage domain of osteopontin mediates breast cancer cell adhesion, proteolytic activity, tumorgenicity, and metastasis , 2011, BMC Cancer.

[88]  A. Giuliano,et al.  Positive Bone Marrow Biopsy Is Associated with a Decreased Disease-Free Survival in Patients with Operable Breast Cancer , 2010 .

[89]  G. Morgan,et al.  First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial , 2010, The Lancet.

[90]  Y. Shiozawa,et al.  Annexin II interactions with the annexin II receptor enhance multiple myeloma cell adhesion and growth in the bone marrow microenvironment. , 2010, Blood.

[91]  Scott A. Guelcher,et al.  Matrix Rigidity Induces Osteolytic Gene Expression of Metastatic Breast Cancer Cells , 2010, PloS one.

[92]  M. Seibel,et al.  Vitamin D deficiency promotes growth of MCF-7 human breast cancer in a rodent model of osteosclerotic bone metastasis. , 2010, Bone.

[93]  T. Plesner,et al.  Multiple myeloma: changes in serum C-terminal telopeptide of collagen type I and bone-specific alkaline phosphatase can be used in daily practice to detect imminent osteolysis* , 2010, European journal of haematology.

[94]  M. Seibel,et al.  Vitamin D deficiency promotes human breast cancer growth in a murine model of bone metastasis. , 2010, Cancer Research.

[95]  T. Plesner,et al.  Myeloma cell‐induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast‐myeloma hybrid cells , 2010, British journal of haematology.

[96]  N. Stoecklein,et al.  Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis , 2010, International journal of cancer.

[97]  K. Pienta,et al.  GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. , 2010, Neoplasia.

[98]  J. Eisman,et al.  Odanacatib, a cathepsin‐K inhibitor for osteoporosis: A two‐year study in postmenopausal women with low bone density , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[99]  W. Walsh,et al.  A novel model of bone‐metastatic prostate cancer in immunocompetent Mice , 2009, The Prostate.

[100]  T. Martin,et al.  What is the true nature of the osteoblastic hematopoietic stem cell niche? , 2009, Trends in Endocrinology & Metabolism.

[101]  T. Wilson,et al.  Enhanced expression and shedding of receptor activator of NF-κB ligand during tumor–bone interaction potentiates mammary tumor-induced osteolysis , 2009, Clinical & Experimental Metastasis.

[102]  Larry Norton,et al.  Latent bone metastasis in breast cancer tied to Src-dependent survival signals. , 2009, Cancer cell.

[103]  Charles P. Lin,et al.  CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. , 2009, Blood.

[104]  C. Klein,et al.  Parallel progression of primary tumours and metastases , 2009, Nature Reviews Cancer.

[105]  Valerie M. Weaver,et al.  A tense situation: forcing tumour progression , 2009, Nature Reviews Cancer.

[106]  M. Zangari,et al.  The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo , 2009, American journal of hematology.

[107]  D. Hume,et al.  Osteal macrophages: a new twist on coupling during bone dynamics. , 2008, Bone.

[108]  I. Weissman,et al.  Endochondral ossification is required for hematopoietic stem cell niche formation , 2008, Nature.

[109]  K. Anderson,et al.  Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma , 2008, Leukemia.

[110]  Haitao Li,et al.  Use of an alpha-smooth muscle actin GFP reporter to identify an osteoprogenitor population. , 2008, Bone.

[111]  David A. Hume,et al.  Osteal Tissue Macrophages Are Intercalated throughout Human and Mouse Bone Lining Tissues and Regulate Osteoblast Function In Vitro and In Vivo1 , 2008, The Journal of Immunology.

[112]  H. Asaoku,et al.  Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation. , 2008, International journal of oncology.

[113]  S. Yaccoby,et al.  Role of decorin in the antimyeloma effects of osteoblasts. , 2008, Blood.

[114]  K. Packman,et al.  Mesenchymal Stem Cells in Early Entry of Breast Cancer into Bone Marrow , 2008, PloS one.

[115]  M. Seibel,et al.  Bone resorption increases tumour growth in a mouse model of osteosclerotic breast cancer metastasis , 2008, Clinical & Experimental Metastasis.

[116]  Roger R. Gomis,et al.  TGFβ Primes Breast Tumors for Lung Metastasis Seeding through Angiopoietin-like 4 , 2008, Cell.

[117]  R. Campanini,et al.  Breast cancer metastases are molecularly distinct from their primary tumors , 2008, Oncogene.

[118]  Jonathan E. Didier,et al.  Synthesis, mechanical properties, biocompatibility, and biodegradation of polyurethane networks from lysine polyisocyanates. , 2008, Biomaterials.

[119]  T. Plesner,et al.  A physical mechanism for coupling bone resorption and formation in adult human bone , 2008 .

[120]  R. Eils,et al.  Systemic spread is an early step in breast cancer. , 2008, Cancer cell.

[121]  G. Mundy,et al.  Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease , 2007, British journal of haematology.

[122]  S. Rha,et al.  Whole genome analysis for liver metastasis gene signatures in colorectal cancer , 2007, International journal of cancer.

[123]  B. Sacchetti,et al.  Self-Renewing Osteoprogenitors in Bone Marrow Sinusoids Can Organize a Hematopoietic Microenvironment , 2007, Cell.

[124]  C. Mancini,et al.  The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. , 2007, Blood.

[125]  S. Khosla,et al.  Remodeling and Vascular Spaces in Bone , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[126]  E. Perez,et al.  Aromatase inhibitors and bone loss. , 2006, Oncology.

[127]  S. Funderud,et al.  Wnt expression and canonical Wnt signaling in human bone marrow B lymphopoiesis , 2006, BMC Immunology.

[128]  Ari Elson,et al.  Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells , 2006, Nature Medicine.

[129]  S. M. Sims,et al.  Regulation of cancer cell migration and bone metastasis by RANKL , 2006, Nature.

[130]  Xunbin Wei,et al.  In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment , 2005, Nature.

[131]  T. Guise,et al.  Breast Cancer Metastasis to Bone: Mechanisms of Osteolysis and Implications for Therapy , 2005, Journal of Mammary Gland Biology and Neoplasia.

[132]  R. Vessella,et al.  Osteoprotegerin in prostate cancer bone metastasis. , 2005, Cancer research.

[133]  T. Martin,et al.  Osteoclast-derived activity in the coupling of bone formation to resorption. , 2005, Trends in molecular medicine.

[134]  Matthew J. Paszek,et al.  The Tension Mounts: Mechanics Meets Morphogenesis and Malignancy , 2004, Journal of Mammary Gland Biology and Neoplasia.

[135]  Paul J. Williams,et al.  Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. , 2004, Blood.

[136]  I. Holen,et al.  Osteoprotegerin (OPG) Produced by Bone Marrow Stromal Cells Protects Breast Cancer Cells from TRAIL-Induced Apoptosis , 2004, Breast Cancer Research and Treatment.

[137]  F. Hamdy,et al.  Human Bone Marrow Stromal Cells Protect Prostate Cancer Cells From TRAIL‐Induced Apoptosis , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[138]  G. Golomb,et al.  Decreased levels of osteopontin and bone sialoprotein II are correlated with reduced proliferation, colony formation, and migration of GFP-MDA-MB-231 cells. , 2004, International journal of oncology.

[139]  M. Michaelson,et al.  Contribution of Androgen Deprivation Therapy to Elevated Osteoclast Activity in Men with Metastatic Prostate Cancer , 2004, Clinical Cancer Research.

[140]  A. Waage,et al.  Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells , 2004, Oncogene.

[141]  Andrés Hidalgo,et al.  Integrin α4β1 involvement in stromal cell-derived factor-1α-promoted myeloma cell transendothelial migration and adhesion: role of cAMP and the actin cytoskeleton in adhesion , 2004 .

[142]  Annuska M Glas,et al.  Gene expression profiles of primary breast tumors maintained in distant metastases , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[143]  D. Scadden,et al.  Osteoblastic cells regulate the haematopoietic stem cell niche , 2003, Nature.

[144]  Haiyang Huang,et al.  Identification of the haematopoietic stem cell niche and control of the niche size , 2003, Nature.

[145]  R. Bataille,et al.  Increased bone remodeling due to ovariectomy dramatically increases tumoral growth in the 5T2 multiple myeloma mouse model. , 2003, Bone.

[146]  D Hölzel,et al.  The process of metastasisation for breast cancer. , 2003, European journal of cancer.

[147]  Paul J. Williams,et al.  Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. , 2003, Blood.

[148]  C. Cordon-Cardo,et al.  A multigenic program mediating breast cancer metastasis to bone. , 2003, Cancer cell.

[149]  I. Fidler,et al.  The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited , 2003, Nature Reviews Cancer.

[150]  David L. Lacey,et al.  Osteoclast differentiation and activation , 2003, Nature.

[151]  E. van Marck,et al.  Zoledronic Acid Treatment of 5T2MM‐Bearing Mice Inhibits the Development of Myeloma Bone Disease: Evidence for Decreased Osteolysis, Tumor Burden and Angiogenesis, and Increased Survival , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[152]  P. Croucher,et al.  Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. , 2003, Cancer research.

[153]  G. Mundy,et al.  Receptor activator of NF‐κB ligand, macrophage inflammatory protein‐1α, and the proteasome , 2003 .

[154]  P. Croucher,et al.  Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. , 2003, Cancer research.

[155]  M. Marton,et al.  A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .

[156]  F. Saad,et al.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2002, Journal of the National Cancer Institute.

[157]  I. Macdonald,et al.  Metastasis: Dissemination and growth of cancer cells in metastatic sites , 2002, Nature Reviews Cancer.

[158]  G. Mundy.  Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities , 2002, Nature Reviews Cancer.

[159]  J. Chirgwin,et al.  Transforming Growth Factor-β Stimulates Parathyroid Hormone-related Protein and Osteolytic Metastases via Smad and Mitogen-activated Protein Kinase Signaling Pathways* , 2002, The Journal of Biological Chemistry.

[160]  F. Hamdy,et al.  Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. , 2002, Cancer research.

[161]  Evan T Keller,et al.  Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. , 2002, Cancer research.

[162]  B. Barlogie,et al.  Myeloma interacts with the bone marrow microenvironment 
to induce osteoclastogenesis and is dependent on osteoclast activity , 2002, British journal of haematology.

[163]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[164]  I. Holen,et al.  Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. , 2001, Blood.

[165]  P. Kantoff,et al.  Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. , 2001, The New England journal of medicine.

[166]  J. Michaeli,et al.  Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[167]  Flemming Melsen,et al.  Cancellous Bone Remodeling Occurs in Specialized Compartments Lined by Cells Expressing Osteoblastic Markers , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[168]  A. Mizokami,et al.  Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. , 2001, The Journal of clinical investigation.

[169]  S. Nilsson,et al.  Spatial localization of transplanted hemopoietic stem cells: inferences for the localization of stem cell niches. , 2001, Blood.

[170]  T. Mcclanahan,et al.  Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.

[171]  A. Hidalgo,et al.  Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. , 2001, Blood.

[172]  A. Waage,et al.  Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells. , 2001, Blood.

[173]  M. Kizaki,et al.  Bone morphogenetic protein-2 induces apoptosis in human myeloma cells with modulation of STAT3. , 2000, Blood.

[174]  W. Kamps,et al.  Effect of single chemotherapeutic agents on the growing skeleton of the rat. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[175]  F. Craig,et al.  Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. , 2000, Blood.

[176]  I. Macdonald,et al.  Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. , 2000, Cancer research.

[177]  Apperley,et al.  Human myeloma cells promote the production of interleukin 6 by primary human osteoblasts , 2000, British journal of haematology.

[178]  B. Smedsrød,et al.  Selective initial in vivo homing pattern of 5T2 multiple myeloma cells in the C57BL/KalwRij mouse , 2000, British Journal of Cancer.

[179]  Lynda F. Bonewald,et al.  Identification and Characterization of a Novel Protein, Periostin, with Restricted Expression to Periosteum and Periodontal Ligament and Increased Expression by Transforming Growth Factor β , 1999 .

[180]  T. Martin,et al.  Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. , 1999, Endocrine reviews.

[181]  R Wieser,et al.  TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. , 1999, The Journal of clinical investigation.

[182]  K. Luzzi,et al.  Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. , 1998, The American journal of pathology.

[183]  E. Thompson,et al.  Bone sialoprotein supports breast cancer cell adhesion proliferation and migration through differential usage of the αvβ3 and αvβ5 integrins , 1998 .

[184]  A. Canfield,et al.  Vascular Pericytes Express Osteogenic Potential In Vitro and In Vivo , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[185]  G. Mundy,et al.  Mechanisms of bone metastasis , 1997, Cancer.

[186]  B F Boyce,et al.  Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. , 1996, The Journal of clinical investigation.

[187]  R. Bataille,et al.  Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies. , 1996, Blood.

[188]  S. Kitazawa,et al.  Integrin αvβ3 Expression by Bone‐residing Breast Cancer Metastases , 1996 .

[189]  K. Pantel,et al.  Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases , 1996, The Lancet.

[190]  A. Parfitt.  Osteonal and hemi‐osteonal remodeling: The spatial and temporal framework for signal traffic in adult human bone , 1994, Journal of cellular biochemistry.

[191]  W. Grzesik,et al.  Bone matrix RGD glycoproteins: Immunolocalization and interaction with human primary osteoblastic bone cells in vitro , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[192]  P. Croucher,et al.  Comparison between the lengths of individual osteoid seams and resorption cavities in human iliac crest cancellous bone. , 1993, Bone and mineral.

[193]  Professor Gregory R. Mundy,et al.  Physiology and Pharmacology of Bone , 1993, Handbook of Experimental Pharmacology.

[194]  K. Mann,et al.  Immunolocalization of noncollagenous bone matrix proteins in lumbar vertebrae from intact and surgically menopausal cynomolgus monkeys , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[195]  K. Anderson,et al.  Characterization of adhesion molecules on human myeloma cell lines. , 1992, Blood.

[196]  R. Baron.  Molecular mechanisms of bone resorption by the osteoclast , 1989, The Anatomical record.

[197]  R. Cote,et al.  Monoclonal Antibodies Detect Occult Breast Carcinoma Metastases in the Bone Marrow of Patients with Early Stage Disease , 1988, The American journal of surgical pathology.

[198]  G. Schlimok,et al.  Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[199]  R. Baron,et al.  Effects of chemotherapeutic agents on bone. I. Short-term methotrexate and doxorubicin (adriamycin) treatment in a rat model. , 1984, The Journal of bone and joint surgery. American volume.

[200]  B. Epker,et al.  Suggested Sequential Mode of Control of Changes in Cell Behaviour in Adult Bone Remodelling , 1965, Nature.

[201]  S Paget,et al.  THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .

[202]  T. Martin,et al.  Basic Principles of Bone Cell Biology , 2013 .

[203]  J. Eastham,et al.  Original Articles RANDOMIZED CONTROLLED TRIAL OF ZOLEDRONIC ACID TO PREVENT BONE LOSS IN MEN RECEIVING ANDROGEN DEPRIVATION THERAPY FOR NONMETASTATIC PROSTATE CANCER , 2012 .

[204]  S. Xuan,et al.  Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells , 2012 .

[205]  T. Martin,et al.  Advances in the biology of bone metastasis: how the skeleton affects tumor behavior. , 2011, Bone.

[206]  Charles P. Lin,et al.  Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy. , 2011, Journal of biomedical optics.

[207]  B. Clarke.  Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer , 2010 .

[208]  Winfried Wiegraebe,et al.  Detection of functional haematopoietic stem cell niche using real-time imaging , 2009, Nature.

[209]  David W. Rowe,et al.  Live-animal tracking of individual haematopoietic stem/progenitor cells in their niche , 2009, Nature.

[210]  Toshio Matsumoto,et al.  Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4–VCAM-1 adhesion and macrophage inflammatory protein-1α and MIP-1β production , 2008, Journal of Bone and Mineral Metabolism.

[211]  W. Dougall,et al.  RANKL acts directly on RANK‐expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes , 2008, The Prostate.

[212]  B. Clarke,et al.  Effect of Once-Weekly Oral Alendronate on Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: A Randomized Trial , 2008 .

[213]  P. Kostenuik,et al.  Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis , 2007, Clinical & Experimental Metastasis.

[214]  P. Croucher,et al.  INVESTIGATING THE INTERACTION BETWEEN OSTEOPROTEGERIN AND RANKL OR TRAIL: EVIDENCE FOR A PIVOTAL ROLE FOR OSTEOPROTEGERIN IN REGULATING TWO DISTINCT PATHWAYS , 2007 .

[215]  P. Kostenuik,et al.  The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft , 2004, Clinical & Experimental Metastasis.

[216]  R. Vessella,et al.  Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[217]  A. Parfitt.  The coupling of bone formation to bone resorption: a critical analysis of the concept and of its relevance to the pathogenesis of osteoporosis. , 1982, Metabolic bone disease & related research.

[218]  T. Martin,et al.  Role of osteoblasts in hormonal control of bone resorption - a hypothesis. , 1982, Calcified tissue international.

[219]  R. Schofield.  The relationship between the spleen colony-forming cell and the haemopoietic stem cell. , 1978, Blood cells.

[220]  J. Bingham.  Letter: Lower oesophageal sphincter. , 1974, Lancet.

[221]  T. Martin,et al.  Breast Cancer Cells Interact with Osteoblasts to Support Osteoclast Formation* , 2022 .